THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC
WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT
KRAS PATIENTS

J 2020

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ, Regina DEMLOVÁ et. al.

Basic information

Original name

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Authors

SEHNALOVÁ, Irena (203 Czech Republic, belonging to the institution), Barbora ŘÍHOVÁ (203 Czech Republic, guarantor, belonging to the institution), Radim NĚMEČEK (203 Czech Republic), Kateřina KINTROVÁ (203 Czech Republic, belonging to the institution) and Regina DEMLOVÁ (203 Czech Republic, belonging to the institution)

Edition

FARMACIA, BUCURESTI, SOC STIINTE FARMACEUTICE ROMANIA, 2020, 0014-8237

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Romania

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.433

RIV identification code

RIV/00216224:14110/20:00116168

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.31925/farmacia.2020.3.25

UT WoS

000543326400025

Keywords in English

bevacizumab; cetuximab; panitumumab; colorectal cancer; cost analysis

Abstract

V originále

Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.

Links

LM2018128, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ and Regina DEMLOVÁ. THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. FARMACIA. BUCURESTI: SOC STIINTE FARMACEUTICE ROMANIA, 2020, vol. 68, No 3, p. 572-578. ISSN 0014-8237. Available from: https://dx.doi.org/10.31925/farmacia.2020.3.25.

@article{1673750,
   author = {Sehnalová, Irena and Říhová, Barbora and Němeček, Radim and Kintrová, Kateřina and Demlová, Regina},
   article_location = {BUCURESTI},
   article_number = {3},
   doi = {http://dx.doi.org/10.31925/farmacia.2020.3.25},
   keywords = {bevacizumab; cetuximab; panitumumab; colorectal cancer; cost analysis},
   language = {eng},
   issn = {0014-8237},
   journal = {FARMACIA},
   title = {THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS},
   url = {http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf},
   volume = {68},
   year = {2020}
}

TY  - JOUR
ID  - 1673750
AU  - Sehnalová, Irena - Říhová, Barbora - Němeček, Radim - Kintrová, Kateřina - Demlová, Regina
PY  - 2020
TI  - THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS
JF  - FARMACIA
VL  - 68
IS  - 3
SP  - 572-578
EP  - 572-578
PB  - SOC STIINTE FARMACEUTICE ROMANIA
SN  - 00148237
KW  - bevacizumab
KW  - cetuximab
KW  - panitumumab
KW  - colorectal cancer
KW  - cost analysis
UR  - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
L2  - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
N2  - Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.
ER  -

SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ and Regina DEMLOVÁ. THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. \textit{FARMACIA}. BUCURESTI: SOC STIINTE FARMACEUTICE ROMANIA, 2020, vol.~68, No~3, p.~572-578. ISSN~0014-8237. Available from: https://dx.doi.org/10.31925/farmacia.2020.3.25.

Detailed Information on Publication Record